Neogenomics CEO Douglas VanOort's 2020 pay rises 13% to $4.1M
Neogenomics reports 2020 executive compensation
By ExecPay News
Published: 2 minutes ago
Neogenomics reported fiscal year 2020 executive compensation information on April 15, 2021.
In 2020, five executives at Neogenomics received on average a compensation package of $1.8M, a 23% increase compared to previous year.
Average pay of disclosed executives at Neogenomics
Douglas M. VanOort, Chief Executive Officer, received $4.1M in total, which increased by 13% compared to 2019. 49% of VanOort's compensation, or $2M, was in option awards. VanOort also received $450K in non-equity incentive plan, $669K in salary, $990K in stock awards, as well as $3K in other compensation.
For fiscal year 2020, the median employee pay was $76,844 at Neogenomics. Therefore, the ratio of Douglas M. VanOort's pay to the median employee pay was 54 to one.
Robert J. Shovlin, President of Clinical Services, received a compensation package of $1.3M, which increased by 1% compared to previous year. 39% of the compensation package, or $502K, was in option awards.
Lawrence M. Weiss, Chief Medical Officer, earned $1.3M in 2020, a 9% increase compared to previous year.
Douglas M. Brown, Chief Strategy and Corporate Development Officer, received $1.2M in 2020.
Kathryn B. McKenzie, Chief Financial Officer, earned $1M in 2020, a 97% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 15, 2021.